Abstracts tagged "SLE"

Abstract Number: 872 • 2014 ACR/ARHP Annual Meeting
Interferon-α and Angiogenic Dysregulation in Pregnant Lupus Patients Destined for Preeclampsia
Danieli Andrade¹, Mimi Kim², Luz P. Blanco³, S. Ananth Karumanchi⁴, Gloria Koo⁵, Patricia M. Redecha⁶, Kyriakos A. Kirou¹, Angela M. Alvarez⁷, Melissa J. Mulla⁷, Mary K. Crow⁸, Vikki Abrahams⁷, Mariana J. Kaplan³ and Jane E. Salmon⁹, ¹Hospital for Special Surgery, New York, NY, ²Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, ³Systemic Autoimmunity Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁵Autoimmunity & Inflammation, Hospital for Special Surgery, New York, NY, ⁶Rheumatology Research, Hospital for Special Surgery, New York, NY, ⁷Yale School of Medicine, New Haven, CT, ⁸Department of Medicine, Hospital for Special Surgery, New York, NY, ⁹Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Pregnant patients with SLE are at increased risk of placental insufficiency and preeclampsia, disorders associated with angiogenic factor imbalance. IFN-α, a critical element in…
Abstract Number: 669 • 2014 ACR/ARHP Annual Meeting
Predicted Chronic Exposure and Dose Selection for Belimumab Administered Subcutaneously to SLE Patients
Herbert Struemper¹, David Roth² and David Gordon³, ¹GlaxoSmithKline, Research Triangle Park, NC, ²GlaxoSmithKline, Philadelphia, PA, ³Immuno-Inflammation R&D, GlaxoSmithKline, King of Prussia, PA
Background/Purpose: Monthly (q4w) intravenously (IV) administered belimumab 10 mg/kg is approved for the treatment of adults with active, autoantibody-positive SLE receiving standard therapy. The present…
Abstract Number: 2551 • 2013 ACR/ARHP Annual Meeting
Pharmacodynamics and Predictive Biomarkers In Patients Treated With Atacicept: Data From The APRIL-SLE Trial
David A. Isenberg¹, David Wofsy², Yong Li³, Daiana Licu⁴, Stephen D. Wax⁵, Caroline Gordon⁶ and Claudia Pena Rossi⁴, ¹Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ²Rheumatology/Immunology, University of California San Francisco and NIAID Autoimmunity Centers of Excellence, San Francisco, CA, ³EMD Serono, Rockland, MA, ⁴Merck Serono S.A., Geneva, Switzerland, ⁵Global Clinical Development Center - Immunology, EMD Serono Inc, Rockland, MA, ⁶Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Atacicept is a fusion protein that inhibits B cell stimulating factors BLyS and APRIL. We examined the pharmacodynamic (PD) effects of atacicept in patients…
Abstract Number: 1621 • 2013 ACR/ARHP Annual Meeting
T Helper 17 Cells and Interferon Type I: Partners In Crime In SLE?
Odilia B.J. Corneth¹, Zana Brkic², Cornelia G. van Helden-Meeuwsen³, Radboud J.E.M. Dolhain⁴, Naomi I. Maria³, Sandra M.J. Paulissen⁴, Nadine Davelaar⁵, Jan Piet van Hamburg⁵, Paul L. Van Daele³, Virgil A. Dalm², Martin van Hagen³, Marjan A. Versnel² and Erik Lubberts⁶, ¹Rheumatology and Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ²Erasmus Medical Center, Immunology, Rotterdam, Netherlands, ³Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ⁴Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, ⁵Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁶Erasmus Medical Center, Rheumatology, Rotterdam, Netherlands
Background/Purpose: A hallmark of systemic autoimmune diseases, such as systemic lupus erythematotsus (SLE), is the increased expression of interferon (IFN) type I inducible genes, the…
Abstract Number: 885 • 2013 ACR/ARHP Annual Meeting
Fatigue In SLE Is Associated With Upregulation Of Interferon- Alpha Related Gene Transcripts
Maureen A. McMahon¹, Jennifer M. Grossman², Bevra H. Hahn³, Lori Sahakian⁴, Isao Matsuura⁵, Elaine Lourenco⁶ and Brian Skaggs⁶, ¹Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Division of Rheumatology, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, ³Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁴Division of Rheumatology, Department of Medicine,, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵UCLA David Geffen School of Medicine, Los Angeles, CA, ⁶Medicine/Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Fatigue is a major complaint in at least 80% of SLE patients, and is often listed as the most disabling symptom of the disease;…
Abstract Number: 578 • 2013 ACR/ARHP Annual Meeting
Ultrasonographic Findings and Inter-Observer Reliability In Danish Patients With Systemic Lupus Erythematosus – a Comparison With Clinical Examination Of Wrist and Hand Joints
Lene Dreyer¹, Søren Jacobsen², Lars Juul³ and Lene Terslev⁴, ¹Internal Medicine - Rheumatology Section, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark, ²Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ³Department of Rheumatology, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark, ⁴Copenhagen University Hospital at Glostrup, Copenhagen, Denmark
Background/Purpose: Patients with systemic lupus erythematosus (SLE) frequently encounter problems of musculoskeletal origin including arthralgia, tenosynovitis and arthritis in varying degrees of severity. Some patients…
Abstract Number: 2522 • 2013 ACR/ARHP Annual Meeting
Novel Autoantibody Against CAF-1 Is a Biomarker For CNS Manifestation in patients With SLE
Kentaro Doe¹, Kazuhisa Nozawa², Kaori Hiruma², Yusuke Yamada¹, Yuko Matsuki¹, Soichiro Nakano¹, Michihiro Ogasawara³ and Yoshinari Takasaki⁴, ¹Department of Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ³Department of internal medicine and rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ⁴Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Proliferating cell nuclear antigen (PCNA) is known to be an autoantigen specifically recognized by antibodies in sera from patients with systemic lupus erythematosus (SLE). Although a prevalence of anti-PCNA…
Abstract Number: 1587 • 2013 ACR/ARHP Annual Meeting
Continuous Variables Of Treatment Interventions In Patients Diagnosed With Systemic Lupus Erythematosus Among Commercially and Medicaid Insured Populations In The U.S
Hong Kan¹, Saurabh Nagar¹, Jeetvan Patel¹, Anna Oh², Daniel J. Wallace³ and Charles T. Molta⁴, ¹GlaxoSmithKline, Research Triangle Park, NC, ²University of California San Francisco, San Francisco, CA, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴GlaxoSmithKline, Philadelphia, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs including the heart, lungs, kidneys, joints, and the nervous system. Standard…
Abstract Number: 765 • 2013 ACR/ARHP Annual Meeting
Angiogenic Factor Dysregulation and Risk Of Adverse Pregnancy Outcome In Lupus Pregnancies
Jane E. Salmon¹, Mimi Kim², Marta M. Guerra³, Michael D. Lockshin⁴, Ware D. Branch⁵, Michelle Petri⁶, Carl A. Laskin⁷, Joan T. Merrill⁸, Lisa R. Sammaritano¹, Jill P. Buyon⁹ and S. Ananth Karumanchi¹⁰, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, ³Rheumatology 3rd Fl Rsrch, Hospital for Special Surgery, New York, NY, ⁴Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁵Obsterics and Gynecology, Univ of Utah, Salt Lake City, UT, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁸Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ¹⁰Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Pregnant women with lupus and APL are at increased risk for adverse outcomes, particularly preeclampsia (PE), yet identification of those destined for complications remains…
Abstract Number: 542 • 2013 ACR/ARHP Annual Meeting
Evidence For Involvement Of C5a Receptor in Human and Murine Lupus Nephritis
Constanze Hess¹, Ditte Tornehave², Peter Helding Kvist², Yvonne Sundström³, Louise Berg³, Iva Gunnarsson⁴, Søren Jacobsen⁵, Claus Haase¹ and Lars Hornum¹, ¹Department of Immunopharmacology, Novo Nordisk A/S, Måløv, Denmark, ²Department of Histology, Novo Nordisk A/S, Måløv, Denmark, ³Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁵Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Background/Purpose: The complement system plays an important role in the pathogenesis of systemic lupus erythematosus (SLE). Apart from the activation of the early components of…
Abstract Number: 2526 • 2013 ACR/ARHP Annual Meeting
An Autoantibody Profile for The Diagnosis Of Systemic Lupus Erythematosus Using the IMMUNARRAY iCHIP™
Chaim Putterman¹, Irene Blanco², Nicole Jordan³, Yves Renaudineau⁴, Vered Daniel Carmi⁵, Rachel Sorek⁵, Ornit Cohen-Gindi⁵, Miriam Lerner⁵, D. Scott Batty⁵, Idan Tamir⁵ and Irun R Cohen^5,6, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ³Department of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁴Unit of immunology, EA 2216, Brest Occidentale University, Brest, France, ⁵ImmunArray, Rehovot, Israel, ⁶Immunology, Weizmann Institute of Science, Rehovot, Israel
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, recurrent, and potentially fatal multisystem inflammatory disorder mainly affecting women. SLE patients produce antibodies to many different self-antigens,…
Abstract Number: 1591 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Atacicept For Prevention Of Flares In Subjects With Moderate To Severe Systemic Lupus Erythematosus (SLE)
David Wofsy¹, David A. Isenberg², Daiana Licu³, Yong Li⁴, Claudia Pena Rossi³ and Caroline Gordon⁵, ¹Rheumatology/Immunology, University of California San Francisco and NIAID Autoimmunity Centers of Excellence, San Francisco, CA, ²Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³Merck Serono S.A., Geneva, Switzerland, ⁴EMD Serono, Rockland, MA, ⁵Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Atacicept is a fusion protein that inhibits B-cell stimulation factors BLyS and APRIL. Levels of BLyS and APRIL are elevated in patients with SLE.…
Abstract Number: 719 • 2013 ACR/ARHP Annual Meeting
Mammalian Target Of Rapamycin (mTOR) Skews T Cell Lineage Development In Systemic Lupus Erythematosus (SLE)
Hiroshi Kato¹ and Andras Perl², ¹Internal Medicine, Division of Rheumatology, SUNY Upstate Medical University, Syracuse, NY, ²Dept of Medicine, SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: mTOR activity is increased in SLE T cells and its blockade has therapeutic efficacy in SLE. Murine studies showed essential roles of mTORC1 in…
Abstract Number: 543 • 2013 ACR/ARHP Annual Meeting
Inhibiting TWEAK (TNF-like weak inducer of apoptosis) Signaling Improves Blood Brain Barrier Integrity and Protects From Neuronal Damage In Murine Neuropsychiatric Lupus
Jing Wen¹, Jessica Doerner², Ariel Stock¹, Jennifer Michaelson³, Linda Burkly³, Maria Gulinello¹ and Chaim Putterman⁴, ¹Albert Einstein College of Medicine, Bronx, NY, ²Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, ³Biogen Idec, Cambridge, MA, ⁴The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by involvement of multiple organs, including the central nervous system. While neuropsychiatric involvement in…
Abstract Number: 1863 • 2013 ACR/ARHP Annual Meeting
SLE Disease Activity In The Mucocutaneus, Vascular and Hematologic Systems Is Associated With An Increase In Plasma Type I Interferon Activity
Elena Gkrouzman¹, Mikhail Olferiev¹, Margaret Robotham¹, Mari Lliguicota¹, Wei-Ti Huang², Elzbieta E. Jacek¹, Kyriakos A. Kirou¹ and Mary K. Crow³, ¹Hospital for Special Surgery, New York, NY, ²Biostatistics, Hospital for Special Surgery, New York, NY, ³Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Type I interferon (IFN-I) has been implicated in SLE pathogenesis, and cross-sectional studies have shown that IFN-I pathway activation is associated with multiple disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].